Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome
NCT05411718Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2023
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of naproxen, aspirin in Lynch syndrome (LS), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2023; status: recruiting.
02
Drugs
naproxenaspirin
03
Conditions
Lynch syndrome (LS)
Beyond the preview
Go deeper on NCT05411718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05411718.